This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2011 by Ramathibodi Hospital.
Recruitment status was:  Recruiting
Information provided by:
Ramathibodi Hospital Identifier:
First received: May 26, 2011
Last updated: May 31, 2011
Last verified: May 2011
Active vitamin D at therapeutic dose may prevent vascular calcification but in supraphysiologic dose may precipitate it.

Condition Intervention Phase
Vascular Calcification Drug: oral alfacalcidol Drug: no drug Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Control Trial of Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease

Resource links provided by NLM:

Further study details as provided by Ramathibodi Hospital:

Primary Outcome Measures:
  • Change in Coronary Artery Calcification [ Time Frame: 6 months and 12 months ]

Estimated Enrollment: 80
Study Start Date: May 2011
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
oral alfacalcidol
Drug: oral alfacalcidol
Oral alfacalcidol 0.5 microgram per day
No Intervention: Control
No drug
Drug: no drug
no drug

Detailed Description:
Active vitamin D compound is used frequently in the treatment of hyperparathyroidism in chronic kidney disease. Recent evidence from animal studies suggested that low dose of active vitamin D may be protective against vascular calcification, whereas high dose could precipitate it. The present study will examine the effect of low dose oral alfacalcidol on coronary artery calcification in predialysis chronic kidney disease patients with hyperparathyroidism.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Predialysis chronic kidney disease with GFR < 90 mL/min/1.73m2
  • PTH above the upper limit of normal
  • serum calcium and phosphate below the upper limit of normal

Exclusion Criteria:

  • changes in GFR>15% during the past 3 months
  • receive elemental calcium>500 mg/day
  • currently taking active vitamin D, oral calcium with elemental calcium>500 mg/day or bisphosphonate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01364688

Contact: Sinee Disthabanchong, MD +6622011116

Faculty of Medicine, Ramathibodi Hospital, Mahidol University Recruiting
Phayathai, Bangkok, Thailand, 10400
Contact: Sinee Disthabanchong, MD    +662011116   
Sponsors and Collaborators
Ramathibodi Hospital
  More Information

Responsible Party: Sinee Disthabanchong, MD, Division of Nephrology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Identifier: NCT01364688     History of Changes
Other Study ID Numbers: 25-05-2011
Study First Received: May 26, 2011
Last Updated: May 31, 2011

Keywords provided by Ramathibodi Hospital:
coronary calcification
vascular calcification
active vitamin D

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Vascular Calcification
Coronary Artery Disease
Urologic Diseases
Renal Insufficiency
Calcium Metabolism Disorders
Metabolic Diseases
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Bone Density Conservation Agents
Physiological Effects of Drugs
Growth Substances processed this record on August 18, 2017